At first glance, an observer might have predicted that shares in VBI Vaccines (Nasdaq: VBIV) would have shot up based on the results of its PROTECT Phase III study, rather than to decline by more than 60% as they did on Monday morning.
The PROTECT study is a comparison of 10 µg dose of Sci-B-Vac, the USA-based company’s trivalent hepatitis B vaccine, compared with a 20 µg dose of the comparator vaccine, GlaxoSmithKline’s (LSE: GSK) Engerix-B.
Both co-primary endpoints were successfully met – including non-inferiority in all adults aged at least 18 years, and superiority in those of 45 years or more.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze